GlassScriptPhysician profile
Allison Cruse
NPI 1588084198
$1,110.96
in general payments reported to CMS, 2019-2025
15 companies · $626 in 2025
The $626 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110 · 2020: $60.94 · 2021: $38.37 · 2022: $190 · 2023: $13.30 · 2024: $72.98 · 2025: $626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $612 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $611.95 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $383.45 | 2019-2025 | Skyrizi |
| Janssen Biotech, INC. | $99.99 | 2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $98.09 | 2025 | Dupixent |
| Lilly USA, LLC | $94.29 | 2019-2025 | Ebglyss, Taltz |
| Galderma Laboratories, L.P. | $61.39 | 2025 | Nemluvio |
| Leo Pharma INC. | $61.33 | 2025 | Anzupgo, Adbry |
| Amgen INC. | $57.94 | 2025 | Otezla |
| Pfizer INC. | $57.11 | 2019-2025 | |
| Genzyme Corporation | $40.60 | 2025 | |
| Novartis Pharmaceuticals Corporation | $35.63 | 2025 | |
| Sun Pharmaceutical Industries INC. | $28.81 | 2025 | |
| Almirall LLC | $28.55 | 2024 | Klisyri |
| Organon LLC | $22.46 | 2025 | |
| Pierre Fabre Pharmaceuticals, INC. | $20.69 | 2022 | |
| Mallinckrodt Hospital Products INC. | $20.63 | 2025 | Acthar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Cruse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.